Veterinary Medicines

Ubrostar Red 100 mg / 280 mg / 100 mg, Intramammary Suspension for Cattle

Authorised
  • Framycetin sulfate
  • Benethamine penicillin
  • Penethamate hydriodide
Download as PDF

Product identification

Medicine name:
Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle
Ubrostar Red 100 mg / 280 mg / 100 mg, Intramammary Suspension for Cattle
Active substance:
  • Framycetin sulfate
  • Benethamine penicillin
  • Penethamate hydriodide
Target species:
  • Cattle
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Framycetin sulfate
    100.00
    milligram(s)
    /
    1.00
    Syringe
  • Benethamine penicillin
    280.00
    milligram(s)
    /
    1.00
    Syringe
  • Penethamate hydriodide
    100.00
    milligram(s)
    /
    1.00
    Syringe
Pharmaceutical form:
  • Intramammary suspension
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle
      • Meat and offal
        10
        day
      • Milk
        37
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ51RC25
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • United Kingdom (Northern Ireland)
Package description:
  • Cardboard box or plastic container containing 20 single useintramammary syringes and 20 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.
  • Cardboard box or plastic container containing 60 single useintramammary syringes and 60 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.
  • Cardboard box or plastic container containing 120 single useintramammary syringes and 120 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health UK Limited
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lohmann Pharma Herstellung GmbH
  • Haupt Pharma Latina S.r.l.
Responsible authority:
  • The Veterinary Medicines Directorate
Authorisation number:
  • Vm 08327/3026
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0271/001
Concerned member states:
  • Belgium
  • Bulgaria
  • Czechia
  • France
  • Hungary
  • Netherlands
  • Poland
  • Romania
  • Slovakia
  • Slovenia
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 23/08/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."